Abstract
The presence of antiphospholipid antibodies has been reported in a large variety of patients with malignancies. Many case reports and reviews have appeared indicating that the presence of the antiphospholipid antibodies is related to thrombotic associations with the antiphospholipid syndrome (APS) in a proportion of these patients. We investigated the frequency of the thrombotic manifestations in 58 patients demonstrating antiphospholipid antibodies and with a history of neoplasia, including haematologic and lymphoproliferative malignancies. Antiphospholipid antibodies were detected by clotting assay [lupus anticoagulant (LAC)] or by enzyme-linked immunosorbent assay [anticardiolipin antibodies (aCL)] according to the Sapporo criteria. Patients, 39/58, suffered from solid tumours and 19/58 patients from malignant haematologic or lymphoproliferative diseases. One patient was suffering simultaneously from two solid tumours and a malignant lymphoma. Among the patients with solid tumours, 18/39 (46%) patients had thromboembolic complications of the antiphospholipid syndrome. Among the patients with haematologic and lymphoproliferative malignancies, only 6/19 (32%) suffered from thromboembolic complications. There was, however, no relation between the titres of aCL antibodies and the clinical manifestations. The presence, but not the titres, of antiphospholipid antibodies may identify a subset of cancer patients with a high risk of developing thrombotic complications. The frequency of thrombosis, however, is lower in aPL-positive patients with lymphoproliferative and haematological malignancies.
Similar content being viewed by others
References
Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311
McNeil HP, Chesterman CN, Krilis SA (1999) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193–280
Shortell CK, Ouriel K, Green RM, Condemi JJ, DeWeese JA (1992) Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis. J Vasc Surg 15:158–165
Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832
Asherson RA (2000) Antiphospholipid antibodies, malignancies and paraproteinemias. J of Autoimmun 15:117–122
Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y (2000) The catastrophic antiphospholipid syndrome–Asherson’s syndrome. Ann Med Interne 154:195–196
Trousseau A (1865) Phlegmasia alba dolens. In: Clinique Medical de L’Hotel Dieu de Paris Vol 3 London. The New Sydenham Society, 1865:94
Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:1–23
Yamamoto T, Ito M, Nagata S, Suzuki H, Togawa A, Nagase M, Hishida A (2000) Catastrophical exacerbation of antiphospholipid syndrome after lung adenocarcinoma biopsy. J Rheumatol 27:2035–2037
Soltesz P, Szekanecz Z, Vegh J, Lakos G, Toth L, Szakall S, Veres K, Szegedi G (2000) Catastrophic antiphospholipid syndrome in cancer. Haematologica 30:303–311
Genvresse I, Buttgereit F, Späth-Schwalbe E, Ziemer S, Eucker J, Possinger K (2000) Arterial thrombosis associated with anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma: a report of two cases. Eur J Haematol 65:344–347
Faiderbe S, Chagnaud JL, Charrier MC et al (1991) Antibodies directed against lipid membrane components in sera of patients with malignant tumours. Cancer Detec Prev 15:199–203
Bessis D, Sotto A, Viaid JP, Berard M, Civana AJ, Boffa M (1995) Trousseau’s syndrome with non-bacterial thrombotic endocarditis: pathogenetic role of antiphospholipid syndrome. Am J Med 98:511–513
Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109–111
Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185–1190
Mackie IJ, Donohoe S, Machin SJ (2000) Lupus anticoagulant measurement. In: Khamashta MA (ed). Hughes syndrome. Antiphospholipid syndrome. Springer, Berlin Heidelberg New York, pp 214–225
Triplett DA, Stocker KF, Unger GA (1993) The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70:925–931
Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russel viper venome time for the diagnosis of lupus anticoagulants. Blood 68:869–874
Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269–275
Tan EM, Cohen AS, Fries JF (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Campbell AL, Pierangeli SS, Wellhausen S, Harris EN (1995) Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73:529–534
Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A (2000) Endothelial activation by aPL. A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 15:237–240
Dobado-Berrios PM, Lopez-Pedreda C, Velazco F, Cuadrado MJ (2001) The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 44:2467–2476
Francis JL, Biggerstaff J, Amirkhosravi A (1998) Hemostasis and malignancy. Semin Thromb Hemost 24:93–109
Zuckerman E, Toubi E, Golan T et al (1995) Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 72:447–451
Yoon KH, Wong A, Shakespeare T, Sivalingham P (2003) High prevalence of the antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12:112–116
Schved JF, Dupuy-Fons C, Biron C et al (1994) A prospective epidemiological study of the occurrence of antiphospholipid antibody; the Montpelier Antiphospholipid (MAP) Study. Haemostasis 24:175–182
Jude B, Goudermand J, Dolle I et al (1988) Lupus anticoagulant: a clinical study of 100 cases. Clin Lab Haematol 10:41–51
Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G (1993) Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost 70:568–572
Lossos IS, Bogomolski-Yahalom V, Hatzner Y (1998) Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Haematol 57:139–143
Lechner K, Pabinger-Fasching I (1985) Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 15:254–262
Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic events in 70 patients. Ann Intern Med 117:303–308
Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicentric study of 114 patients. Am J Med 96:3–9
Liozon E, Loustaud V, Jauberteau MO, Jaccard A, Soria P, Bordessoule D, Julia A, Vidal E (2001) Non-simultaneous malignant lymphoma and antiphospholipid syndrome: 4 cases. Rev Med Interne 22:360–370
Sciarra A, Staai R, Stipa B et al (1995) Antifosfolipid prevalenza, significato clinico e correlazione con I livell di citochine nella leucemia mieloice e mel linfomanon-Hodgkin. Recentl Prog Med 86:57–62
Genvresse I, Lüftner D, Späth-Schwalbe E, Buttgereit F (2002) Prevelance and clinical significance of anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 68:84–90
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miesbach, W., Scharrer, I. & Asherson, R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 25, 840–844 (2006). https://doi.org/10.1007/s10067-005-0181-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0181-2